Skip to main content
Equibles
AVIR logo

AVIR · Atea Pharmaceuticals, Inc.

Track AVIR — free

Use AVIR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.83 +0.01 (+0.17%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$467.59M
Shares
80.20M

AVIR metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.83
Market cap
$467.59M

Price action

19 metrics
Price change (1W)
+8.8%
Price change (30D)
+16.1%
Price change (3M)
+37.2%
Price change (6M)
-1.0%
Price change (YTD)
+63.3%
Price change (1Y)
+75.1%
Trailing year
Price change (5Y)
-79.8%
52-week high
$6.15
52-week low
$2.82
Change from 52-week high
-5.2%
Change from 52-week low
+106.7%
Annualized volatility
49.6%
Beta
0.6
RSI (14D)
69.3
Price vs SMA 50
+16.1%
Price vs SMA 200
+26.5%
Avg volume (3M)
318,426
Relative volume
0.6
Average dollar volume
$1.53M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 75.1%
P / book
2.3
reciprocal yield 43.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-35.3%

Historical valuation

8 metrics
P / E historical average (3Y)
25.9×
reciprocal yield 3.9%
P / E historical average (5Y)
25.9×
reciprocal yield 3.9%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
39.4%
Trailing 12 months
Net margin
34.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$183.61M
Net income (TTM)
−$165.29M
Trailing 12 months
Diluted EPS (TTM)
$-2.08
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-4.91

Growth

11 metrics
Revenue growth YoY
+622.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$351.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-4.4%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-81.0%
Return on assets
-71.2%
Debt / equity
—
Current ratio
8.1
EBITDA (TTM)
−$183.19M
Free cash flow (TTM)
—
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$76.55M
Latest balance sheet
Cash & equivalents
$76.55M
Total assets
$232.28M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$152.07M
Capital expenditures (TTM)
$1.94M
R&D (TTM)
$155.45M
SG&A (TTM)
—
Stock compensation (TTM)
$16.21M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
125
13F filer change QoQ
-2
Institutional ownership
74.1%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 26.6 days to cover
Days to cover
26.6d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1593899 CUSIP 04683R106 13F (30d) 86 filings 86 filers Visit website Investor relations